Articles From: Pfizer and Breast Cancer Leaders Join Together to Increase Understanding and Dispel Myths about Metastatic Breast Cancer to PFSweb Acquires Digital Creative Agency LiveAreaLabs


2014/10/8
This October, Pfizer Inc. is uniting with leaders in the breast cancer community in a public call-to-action to expand the breast cancer dialogue to include metastatic breast cancer.
Sign-up for Pfizer and Breast Cancer Leaders Join Together to Increase Understanding and Dispel Myths about Metastatic Breast Cancer investment picks
2014/12/10
Nearly one out of every two (45.25%) American women will be menopausal or approaching menopause next year.
Sign-up for Pfizer and Brenda Strong Encourage Women to Change the Conversation on Sexual Health Post-Menopause investment picks
Pfizer Inc. today announced the New Drug Application (NDA) for palbociclib has been accepted for filing and granted Priority Review by the United States Food and Drug Administration (FDA). This NDA requests FDA approval of palbociclib, in combination with letrozole, as a first-line treatment for postmenopausal women with estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer who have not received previous systemic treatment for their advanced disease.
Sign-up for Pfizer Announces FDA Acceptance Of Palbociclib New Drug Application With Priority Review investment picks
2014/10/13
By Chelsey Dulaney Pfizer Inc. said Monday that its experimental breast-cancer treatment, palbociclib, has been granted priority review by the U.S. Food and Drug Administration, potentially speeding the approval process by up to four months.
Sign-up for Pfizer breast cancer treatment granted FDA priority review status investment picks
Pfizer Inc. (NYSE:PFE) today announced that it has completed the acquisition of Baxter International Inc.’s portfolio of marketed vaccines.
Sign-up for Pfizer Completes Acquisition of Baxter’s Marketed Vaccines investment picks
Pfizer Inc. (NYSE:PFE) today announced that it has completed its acquisition of the pharmaceutical development company, InnoPharma, Inc., following receipt of United States (U.S.) regulatory approval from all government authorities required by the agreement and other closing conditions.
Sign-up for Pfizer Completes Acquisition Of InnoPharma investment picks
2014/10/23
The board of directors of Pfizer Inc. today declared a 26-cent fourth-quarter 2014 dividend on the company’s common stock, payable December 2, 2014, to shareholders of record at the close of business on November 7, 2014.
Sign-up for Pfizer Declares 26-Cent Fourth-Quarter 2014 Dividend investment picks
By Tess Stynes Pfizer Inc. said it notified Pain Therapeutics Inc. that it is ending its agreement to develop and commercialize an investigational extended-release version of oxycodone.
Sign-up for Pfizer ends agreement to develop Remoxy investment picks
Pfizer Inc. (NYSE:PFE) announced today two strategic decisions to expand the company’s rare disease research and development activities through the establishment of a gene therapy platform to investigate potential treatments for patients.
Sign-up for Pfizer Expands Rare Disease Research with Establishment of Gene Therapy Platform investment picks
Pfizer Inc. (NYSE:PFE) announced today that it has entered into an agreement with Merck KGaA, Darmstadt, Germany, to jointly develop and commercialize MSB0010718C, an investigational anti-PD-L1 antibody currently in development by Merck KGaA as a potential treatment for multiple types of cancer.
Sign-up for Pfizer Forms Global Strategic Alliance with Merck KGaA, Germany, to Jointly Develop and Commercialize Anti-PD-L1 to Accelerate Presence in Immuno-Oncology investment picks
2014/9/19
The Pfizer Foundation today announced $2 million in grant funding for pilot programs to improve immunization coverage in Africa.
Sign-up for Pfizer Foundation Provides $2 Million In Grants To Support ‘Last-Mile’ Vaccine Coverage In Africa investment picks
By Jonathan D.
Sign-up for Pfizer held takeover talks with Actavis investment picks
Pfizer Inc. announced today that it will present data for several of its marketed and investigational medicines for inflammatory and immunological conditions at the American College of Rheumatology (ACR) / Association of Rheumatology Health Professionals (ARHP) 2014 Annual Meeting (November 14-19, Boston, Massachusetts). Twenty-one abstracts for XELJANZ ® (tofacitinib citrate) will be presented, including the six-year safety and efficacy analyses from long-term extension (LTE) studies and a summary of real-world patient experience, additional post-hoc analyses from the clinical development program, and health and economics outcomes research, adding to the substantial body of evidence for XELJANZ as an oral treatment option for moderate to severe rheumatoid arthritis (RA). Data will also be presented for several additional Pfizer assets, including PF-04236921, an investigational
Sign-up for Pfizer Highlights Leadership in Rheumatology and Inflammation with Data to be Presented at the ACR/ARHP 2014 Annual Meeting investment picks
2014/11/5
Pfizer Inc. invites investors and the general public to listen to a webcast of a discussion with Albert Bourla, Group President, Vaccines, Oncology and Consumer Healthcare Business, at the Credit Suisse 2014 Healthcare Conference on Wednesday, November 12, 2014 at 8:00 a.m. Mountain Standard Time.
Sign-up for Pfizer Invites Public To Listen To Webcast Of Pfizer Discussion At Healthcare Conference investment picks
2014/9/23
Pfizer Inc. invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EDT on Tuesday, October 28, 2014.
Sign-up for Pfizer Invites Public to View and Listen to Webcast of October 28 Conference Call with Analysts investment picks
Pfizer Inc. (NYSE:PFE) announced today that the U.S. Food and Drug Administration (FDA) has granted accelerated approval of TRUMENBA ® (meningococcal group B vaccine) for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B in individuals 10 through 25 years of age.
Sign-up for Pfizer Receives FDA Accelerated Approval for TRUMENBA® (Meningococcal Group B Vaccine) for the Prevention of Invasive Meningococcal B Disease in Adolescents and Young Adults investment picks
Pfizer Inc. (NYSE:PFE) reported financial results for third-quarter 2014.
Sign-up for PFIZER REPORTS THIRD-QUARTER 2014 RESULTS investment picks
Pfizer shares (PFE) rose 1.4% in after-hours trade Thusday after the blue-chip drug maker said it has authorized a new $11 billion share buyback program, to be "utilized over time." That is in addition to the $1.3 billion left in its previous repurchase program.
Sign-up for Pfizer shares rise after new $11 billion share buyback program investment picks
Pfizer Inc. (NYSE: PFE ) has notified Pain Therapeutics, Inc. (NASDAQ: PTIE ) that it has decided to discontinue its agreement to develop and commercialize REMOXY™ (oxycodone) Extended-Release Capsules CII, an investigational extended-release oral formulation of oxycodone.
Sign-up for Pfizer to Discontinue Agreement on REMOXY™ (oxycodone) Extended-Release Capsules CII investment picks
Pfizer Inc. (NYSE:PFE) announced today that it will present data from a Phase 1/Phase 2 study evaluating the safety, tolerability and immunogenicity of a single-dose vaccine of Pfizer’s investigational 4-antigen Staphylococcus aureus ( S.
Sign-up for Pfizer to Present New Data Evaluating Safety, Tolerability and Immunogenicity of its Investigational Staphylococcus aureus Vaccine Candidate at IDWeek 2014™ investment picks
Pfizer Inc. (NYSE:PFE) announced today it will present the results of a Phase 2, randomized study to evaluate co-administration of the company’s investigational meningococcal group B vaccine, bivalent recombinant LP2086 (rLP2086), with a licensed quadrivalent human papillomavirus vaccine (HPV4), at IDWeek 2014™ in Philadelphia.
Sign-up for Pfizer To Present Safety And Immunogenicity Data From A Phase 2 Study Of Its Investigational Meningococcal Group B Vaccine, Bivalent rLP2086, Co-Administered With A Licensed Human Papillomavirus Vaccine investment picks
2014/10/23
Pfizer Inc. announced today that the U.S. District Court for the District of Delaware upheld its basic patent and the L-malate salt patent covering SUTENT® (sunitinib malate) capsules.
Sign-up for Pfizer Wins SUTENT® Patent Case In Delaware District Court investment picks
2014/11/17
By Natalia Drozdiak FRANKFURT--
Sign-up for Pfizer, Germany's Merck to Develop Tumor Treatment investment picks
2014/11/17
By Natalia Drozdiak and Christopher Alessi FRANKFURT--
Sign-up for Pfizer, Germany's Merck to Develop Tumor Treatment -- Update investment picks
2014/11/17
By Natalia Drozdiak and Christopher Alessi FRANKFURT--
Sign-up for Pfizer, Germany's Merck to Develop Tumor Treatment --2nd Update investment picks
By Natalia Drozdiak FRANKFURT --
Sign-up for Pfizer, Merck strike deal to develop cancer tumor treatment investment picks
Pfizer's stock (PFE) fell 1.6% in premarket trade Monday, after the blue-chip drug maker lowered its 2014 profit outlook following its agreement to team up with Germany's Merck KGaA to develop new cancer treatments.
Sign-up for Pfizer's stock drops after profit outlook cut investment picks
Pfizer Inc.'s stock (PFE) rose 1.8% in premarket trade Tuesday, after the drug giant reported better-than-expected third-quarter profit and sales.
Sign-up for Pfizer's stock rallies after earnings, sales beat expectations investment picks
Pfizer Inc. (NYSE:PFE) today announced the publication of a clinical study in the Journal of Clinical Psychiatry showing comparable sexual function in adult patients diagnosed with major depressive disorder (MDD) treated daily with PRISTIQ Extended Release Tablets 50mg and 100mg doses versus placebo.
Sign-up for Pfizer’s PRISTIQ® (desvenlafaxine) Demonstrates Low Potential For Sexual Dysfunction in Adults with Major Depressive Disorder investment picks
http://media.marketwire.com/attachments/201409/276763_pfs.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1146422&ProfileId=051205&sourceType=1 ALLEN, TX --
Sign-up for PFSweb Acquires Digital Creative Agency LiveAreaLabs investment picks
Premium Membership: Features and Benefits
Wide-Moat Screener for Stocks

Put a moat around your portfolio. Sniff out the most promising opportunities that can ride through any market.

Gold Medalist Screener for Funds

Narrow the available universe of 5000 funds to the top rated gold and silver. Then, sort for manager tenure, expense ratio, risk and return to create your own index-beating fund watchlist.

Thousands of Premium Analyst Reports

While many of our competitors measure a stock's worth with a computer program, Morningstar's staff of 150+ analyst sift through company fillings, financial data and a wealth of other sources to deliver an unvarnished review of any investment. In fact, twelve Morningstar analysts have been recognized by WSJ as "Best on the Street" in the US.

Premium Portfolio Monitor

Make decisions with confidence. Load your investments into our research center and automatically connect to all our proprietary tools and data points.

Mobile

Never be without critical research. Free with your active membership, take our Premium data and guidance wherever you go with Morningstar for iPad®, iPhone®, and Android apps.

Morningstar's Guarantee

We're looking out for you. If after your 14-day free trial, you find that a Morningstar Premium membership is not for you, cancel any time and we'll be happy to refund the unused portion - no questions asked.

Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Articles From: Pfizer and Breast Cancer Leaders Join Together to Increase Understanding and Dispel Myths about Metastatic Breast Cancer to PFSweb Acquires Digital Creative Agency LiveAreaLabs
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent